PARP inhibitors in ovarian cancer: overcoming resistance with combination strategies
Rowan Miller(Queen Mary University of London), Jung‐Yun Lee(Yonsei University), Karim El-Shakankery(University College Hospital)
Cited by 54
Related Papers
Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial
|Journal of Clinical Oncology|2023|882
ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer
|Annals of Oncology|2020|478
ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A
|Nature Communications|2016|386